BOSTON, Mass., September 15, 2025 – Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company pioneering molecular glue degrader (MGD)-based medicines, today announced a new collaboration with Novartis to develop degraders for immune-mediated diseases. The agreement follows their 2024 deal on VAV1 degraders and underscores the momentum of Monte Rosa’s QuEEN™ discovery engine in addressing historically undruggable targets.
Under the terms, Monte Rosa receives an upfront payment of $120 million and may earn up to $5.7 billion in option, milestone, and royalty payments as Novartis advances select immunology degrader programs.
Science Significance
Molecular glue degraders represent a cutting-edge therapeutic modality designed to hijack the cell’s natural protein degradation system. Unlike traditional inhibitors, MGDs can eliminate disease-causing proteins entirely, including those once considered undruggable. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) platform integrates AI/ML, structural biology, and proteomics to design MGDs with high selectivity.
This collaboration specifically targets immune-mediated diseases driven by Th1, Th2, and Th17 pathways, which have long challenged drug developers. By combining Monte Rosa’s degrader discovery expertise with Novartis’s global development capabilities, the partnership could accelerate the arrival of transformative therapies for autoimmune and inflammatory conditions.
Regulatory Significance
Advertisement
From a regulatory perspective, the deal reinforces the growing recognition of targeted protein degradation as a validated therapeutic class. Novartis brings deep experience in navigating complex regulatory frameworks for immune-mediated diseases.
Importantly, Monte Rosa and Novartis are expected to pursue multi-jurisdictional development strategies, positioning programs for eventual submissions in the U.S., Europe, and other key markets. By leveraging Novartis’s established regulatory infrastructure, Monte Rosa’s degrader programs could advance more swiftly into clinical trials and ultimately reach patients faster.
Business Significance
Financially, the collaboration represents a major milestone for Monte Rosa. The $120 million upfront payment, combined with potential milestone payments of up to $5.7 billion and royalties on global sales, significantly extends Monte Rosa’s cash runway.
This strengthened financial position enables Monte Rosa to simultaneously advance its wholly owned pipeline, which includes candidates in oncology and immunology, while benefiting from Novartis’s resources to progress partnered programs. Analysts note that this partnership provides Monte Rosa with both immediate liquidity and long-term upside potential, making it one of the most substantial biotech deals in 2025.
Patients’ Significance
For patients, the collaboration holds meaningful promise. Autoimmune and inflammatory diseases often involve chronic symptoms, limited treatment durability, and serious side effects from current therapies such as immunosuppressants or biologics.
MGDs could offer more precise and durable interventions by directly degrading disease-driving proteins. This approach has the potential to deliver longer-lasting responses, fewer adverse effects, and improved quality of life. The fact that Monte Rosa’s degraders can address proteins beyond the reach of existing modalities further expands therapeutic possibilities for patients living with severe immune conditions.
Policy Significance
At a policy level, the partnership between Monte Rosa and Novartis reflects broader trends encouraging public-private collaboration and investment in novel drug discovery platforms. Governments and regulators are increasingly supportive of technologies like protein degradation, which align with health system priorities around innovation, unmet medical needs, and cost-effective care.
The scale of this agreement also highlights the strategic importance of biotech–pharma alliances in ensuring that groundbreaking science translates into accessible therapies. If successful, the programs developed under this deal could influence reimbursement frameworks and healthcare policies for future degrader-based medicines.
Transaction Highlights
Under the terms of the agreement, Monte Rosa will receive an upfront payment of $120 million from Novartis, along with additional option maintenance payments to sustain the partnership as programs advance. Novartis gains an exclusive license to one undisclosed discovery target and options to license two further programs from Monte Rosa’s preclinical immunology portfolio. Should Novartis exercise these options and achieve development, regulatory, and sales milestones across the programs, Monte Rosa could receive up to $5.7 billion in total deal value, positioning this collaboration among the most significant biotech partnerships of 2025. In addition, Monte Rosa will be entitled to tiered royalties on global net sales in the high single to low double-digit range, ensuring long-term value if the partnered therapies succeed commercially. Importantly, Monte Rosa’s publicly disclosed pipeline programs—including MRT-6160, MRT-8102, and MRT-2359—remain outside the scope of this agreement, allowing the company to continue advancing these candidates independently while benefiting from the financial and strategic advantages of the Novartis collaboration.
Source: Monte Rosa Therapeutics, Inc. Press Release
